Find and Pitch Jounalists, Get Your Story Covered

Tags: statins statin lipid statin therapy kidney disease

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 6 days ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 14 days ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 30 days ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 2 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 2 months ago STAT+: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more - 2 months ago STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more - 2 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 3 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 5 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a GLP-1 side effect, U.K. clinical trial transparency, and more - 6 months ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - 9 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 9 months ago STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal - 10 months ago STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge - 10 months ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - 11 months ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - 11 months ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - 12 months ago
2	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Grants Breakthrough Therapy Designation to Plozasiran for Familial Chylomicronemia Syndrome - 7 days ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 14 days ago STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH - 6 months ago STAT+: First medicine developed to treat MASH expected to be approved soon - 6 months ago STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study - 7 months ago STAT+: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study - 9 months ago STAT+: In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients - 10 months ago STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor - 11 months ago
4	Randy Dotinga MedPage Today Indie scribbler, advocate. Board member, @ahcj. San Diego WritingAdvocacy	Statin Use Linked to Higher Risk of Glaucoma - about 2 months ago
5	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: A second Roche obesity drug shows promise in early studies - 2 months ago STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH - 7 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - 9 months ago STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial - 10 months ago STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial - 12 months ago
6	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: FDA rejects Rocket Pharmaceuticals’ gene therapy for ultra-rare condition, another setback for field - 3 months ago STAT+: Avidity Biosciences says its experimental drug showed potential against form of muscular dystrophy - 3 months ago
7	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease - 3 months ago STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug - 10 months ago STAT+: After decades in use, heart stents finally beat placebo. It took a bold researcher - 10 months ago
8	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor - 5 months ago STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill - 5 months ago STAT+: Alnylam’s twice-a-year drug lowered blood pressure when combined with common pills - 5 months ago STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure - 6 months ago STAT+: Merck drug for rare cardiovascular condition approved in U.S. - 6 months ago STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label - 6 months ago STAT+: Liver disease MASH is next target for obesity drugs in development - 7 months ago STAT+: What comes after Wegovy? The quest to eradicate obesity - 9 months ago STAT+: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds - 9 months ago STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial - 10 months ago STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle - 10 months ago STAT+: Anthos stroke drug appears safer than common blood thinner in mid-stage trial - 10 months ago
9	Crystal Phend MedPage Today Contributing editor at MedPage Today. Personal views. HealthcareEditing	Third-Generation PCSK9 Inhibitor Cuts Cholesterol With Single, Small, Monthly Shot - 5 months ago Self-Selection for Statin Appears Safe, Effective - 5 months ago Antisense Drug Slashes High Triglycerides - 5 months ago
10	Ed Susman MedPage Today Freelance Medical journalist. Owns medical site. West Palm Beach, Florida medical journalismwritinghealthcare	Apolipoprotein A1 Infusions After Acute MI Disappoint in Phase III Trial - 5 months ago

Journalists covering statin